Cooperation Among Regulators: Impact on Stakeholders

Track:
Public Policy/ Health Care Compliance/ Law

Day & Time:
June 24, 2:30PM - 4:00PM

Session Number:
135

Room Number:
254AB

Level:
Intermediate

Type:
Session

Title:
Cooperation Among Regulators: Impact on Stakeholders

Chair(s):
Marie Allison Dray, MA,MBA
President
International Regulatory Affairs Group LLC, United States

Murray M. Lumpkin, MD,MSc
Commissioner's Senior Advisor and Representative for Global Issues, OC
FDA , United States

Description:
In this session, the audience will hear views from the leaders of three of the most influential drug regulatory agencies - The Health Products and Food Branch of Health Canada, the European Medicines Agency and the US FDA - on important issues.

Learning Objective(s):
Discuss current actions in public policy resulting from interagency actions and strategic communications; Determine the impact on organizations of stakeholders.

Presentation(s) & Speaker(s):
FDA Point of View
Margaret A. Hamburg, MD
Commissioner
FDA, United States

EMA Point of View
Guido Rasi, MD
Executive Director
European Medicines Agency, European Union, United Kingdom

Health Canada Point of View
Paul Glover, MBA
Assistant Deputy Minister of the Health Products and Food Branch
Health Canada, Canada